Anti-Human Siglec-3/CD33 Recombinant Nanobody (SAA2052) (HB185013)

Name: Anti-Human Siglec-3/CD33 Recombinant Nanobody (SAA2052)
Brand: abinScience
SKU: HB185013
Price: 191 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50ug
100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HB185013

Marca

abinScience

Descripción

Anti-Human CD33 Nanobody (SAA2052) [SAA2052] (HB185013) is a alpaca monoclonal antibody detecting CD33 in ELISA, FCM. Suitable for Human and Cynomolgus.

Highlights

●Flow Cytometry — Validated for flow cytometry applications.

Reactividad de especies

Human, Monkey

Aplicaciones

ELISA, FCM, WB

Especie huésped

Alpaca

Clonalidad

Monoclonal

Isotipo

VHH-8His-Cys-tag

ID de clon

SAA2052

Aplicaciones probadas

Objetivo

Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3

Nivel de endotoxinas

Please contact with the lab for this information.

Pureza

>95% as determined by SDS-PAGE.

Purificación

Purified by Nickel column.

Número de acceso

P20138

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000
WB	1:500-1:2000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Myeloid cell surface antigen CD33 is a ~39 kDa protein. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans. Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK. These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2. In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules. CD33 is the therapeutic target of gemtuzumab ozogamicin (Mylotarg).

1. Vitale, C. et al. (1999) Proceedings of the National Academy of Sciences of the United States of America 96, 15091-6. PMID: 10611343

2. Vitale, C. et al. (2001) Proceedings of the National Academy of Sciences of the United States of America 98, 5764-9. PMID: 11320212

3. Lajaunias, F. et al. (2005) European journal of immunology 35, 243-51. PMID: 15597323

4. Freeman, SD. et al. (1995) Blood 85, 2005-12. PMID: 7718872

5. Paul, SP. et al. (2000) Blood 96, 483-90. PMID: 10887109

6. Son, M. et al. (2017) Scientific reports 7, 270. PMID: 28325905

7. Taylor, VC. et al. (1999) The Journal of biological chemistry 274, 11505-12. PMID: 10206955

8. Ulyanova, T. et al. (1999) European journal of immunology 29, 3440-9. PMID: 10556798

Nota

For research use only.

Imágenes

SDS-PAGE

SDS-PAGE for Anti-Human CD33 Recombinant Nanobody (SAA2052)
Bioactivity

Detects CD33 (Catalog No: HB185011) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CD33 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD33 (Catalog No: HB185011)